^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    melphalan

    i
    Other names: L-PAM, L-sarcolysin, phenylalanine mustard
    Company:
    Generic mfg.
    Drug class:
    Alkylating agent
    Related drugs:
    1m
    AugMMent: GMMG-HD11/DSMM XXI/64007957MMY3010 (clinicaltrials.gov)
    P3, N=399, Not yet recruiting, University of Heidelberg Medical Center
    New P3 trial
    |
    lenalidomide • bortezomib • Darzalex (daratumumab) • melphalan • Tecvayli (teclistamab-cqyv)
    2ms
    Prospective Observational Study of Outcomes After Gemcitabine, Docetaxel, Melphalan, and Carboplatin With Autologous Stem Cell Transplantation in Pediatric Relapsed/Refractory Germ Cell Tumors (clinicaltrials.gov)
    P=N/A, N=30, Recruiting, M.D. Anderson Cancer Center
    New trial
    |
    carboplatin • gemcitabine • docetaxel • melphalan
    2ms
    The Effect of Diabetes mellitus Type2 on Mobilization and Autologous Hematopoietic Stem Cell Transplantation Outcomes. (PubMed, Indian J Hematol Blood Transfus)
    However, various factors can lead to failure in hematopoietic stem cell mobilization in some patients, including age, type of malignancy, chemotherapy regimens (such as fludarabine, Melphalan, and Lenalidomide), radiotherapy, bone marrow cellularity, and comorbidities. It is crucial to recognize that diabetes can significantly affect the outcomes of hematopoietic stem cell transplantation. Factors such as poor stem cell mobilization, prolonged engraftment times, and increased need for blood product transfusions underscore the importance of considering diabetes in HSCT candidates.
    Journal
    |
    CD34 (CD34 molecule)
    |
    lenalidomide • melphalan • fludarabine IV
    2ms
    Pegargiminase Suppresses the Fanconi Anemia Pathway and Promotes Melphalan-Induced DNA Double-Strand Breaks in Uveal Melanoma. (PubMed, Pigment Cell Melanoma Res)
    ADI-PEG20 downregulated multiple genes of the Fanconi anemia pathway and synergized with melphalan to increase DNA double-strand breaks. Melphalan and pegargiminase is a rational new drug combination that warrants clinical testing in uveal melanoma.
    Journal
    |
    ASS1 (Argininosuccinate synthase 1)
    |
    melphalan • Hepacid (pegargiminase)
    2ms
    Combination Chemotherapy, Total Body Irradiation, and Donor Blood Stem Cell Transplant in Treating Patients With Secondary Myelofibrosis (clinicaltrials.gov)
    P1, N=22, Active, not recruiting, City of Hope Medical Center | Trial completion date: May 2026 --> Apr 2027 | Trial primary completion date: May 2026 --> Apr 2027
    Trial completion date • Trial primary completion date
    |
    cyclophosphamide • melphalan • fludarabine IV
    2ms
    NCI-2020-04920: Personalized Autologous Transplant for Multiple Myeloma (clinicaltrials.gov)
    P1, N=90, Recruiting, Emory University | Trial completion date: Dec 2026 --> Dec 2027 | Trial primary completion date: Jun 2026 --> Jun 2027
    Trial completion date • Trial primary completion date
    |
    CELLSEARCH®
    |
    melphalan
    2ms
    Efficacy and Safety of the CloB2M (Clofarabine Combined With Busulfan and Melphalan) Conditioning Regimen in Allogeneic Hematopoietic Stem Cell Transplantation for Adult Patients With Acute Myeloid Leukemia in First Complete Remission (clinicaltrials.gov)
    P=N/A, N=30, Not yet recruiting, Institute of Hematology & Blood Diseases Hospital, China
    New trial
    |
    clofarabine • melphalan • busulfan
    2ms
    Haplo-Cord HSCT for AML/MDS (clinicaltrials.gov)
    P=N/A, N=82, Recruiting, Fujian Medical University Union Hospital | N=180 --> 82
    Enrollment change
    |
    KIT (KIT proto-oncogene, receptor tyrosine kinase) • NPM1 (Nucleophosmin 1) • RUNX1 (RUNX Family Transcription Factor 1) • RUNX1T1 (RUNX1 Partner Transcriptional Co-Repressor 1) • CEBPA (CCAAT Enhancer Binding Protein Alpha)
    |
    NPM1 mutation • KIT mutation
    |
    cytarabine • cyclophosphamide • melphalan • fludarabine IV • busulfan
    2ms
    NCI-2018-03732: Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma (clinicaltrials.gov)
    P2, N=42, Completed, National Cancer Institute (NCI) | Active, not recruiting --> Completed | Trial completion date: Sep 2026 --> Mar 2026
    Trial completion • Trial completion date
    |
    MYCN (MYCN Proto-Oncogene BHLH Transcription Factor)
    |
    MYCN amplification
    |
    cisplatin • carboplatin • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • daunorubicin • topotecan • melphalan • thiotepa • Qarziba (dinutuximab beta) • Unituxin (dinutuximab) • dexrazoxane • Leukine (sargramostim)
    2ms
    Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders (clinicaltrials.gov)
    P2, N=260, Active, not recruiting, City of Hope Medical Center | Trial completion date: Apr 2026 --> Mar 2027
    Trial completion date
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-B (Major Histocompatibility Complex, Class I, B)
    |
    cyclophosphamide • etoposide IV • sirolimus • melphalan • fludarabine IV • busulfan • cyclosporine
    2ms
    High Dose Therapy and Autologous Stem Cell Transplantation Followed by Infusion of Chimeric Antigen Receptor (CAR) Modified T-Cells Directed Against CD19+ B-Cells for Relapsed and Refractory Aggressive B Cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1, N=17, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Apr 2026 --> Apr 2027 | Trial primary completion date: Apr 2026 --> Apr 2027
    Trial completion date • Trial primary completion date
    |
    cytarabine • etoposide IV • carmustine • melphalan • Neulasta (pegfilgrastim) • vadacabtagene leraleucel (JCAR015)
    2ms
    Improving public cancer care by implementing precision medicine in Norway (2023-507894-16-00)
    P1/2, N=1000, Recruiting, Oslo University Hospital HF | N=6000 --> 1000
    Enrollment change
    |
    Avastin (bevacizumab) • Lynparza (olaparib) • Mekinist (trametinib) • Tecentriq (atezolizumab) • Zelboraf (vemurafenib) • Tafinlar (dabrafenib) • Rozlytrek (entrectinib) • imatinib • Alecensa (alectinib) • Cotellic (cobimetinib) • bortezomib • Piqray (alpelisib) • Zejula (niraparib) • Retevmo (selpercatinib) • Zykadia (ceritinib) • fulvestrant • Jemperli (dostarlimab-gxly) • Pemazyre (pemigatinib) • Tepmetko (tepotinib) • Tabrecta (capmatinib) • dexamethasone • Erivedge (vismodegib) • melphalan • dactinomycin • hydroxyurea • Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf)